TrialSignal transduction and targeted therapy2025

Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial.

Shuo Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.